Related Experiment Video
Updated: Mar 28, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
A pivotal role for HOXB7 protein in endocrine resistant breast cancer
Kideok Jin1, Saraswati Sukumar1
1Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abstract:
HOXB7 is a homeodomain containing transcription factor which plays a pivotal role in tamoxifen resistant breast cancer. Our work has shown that overexpression of HOXB7 renders cells tamoxifen resistant by mobilizing a number of receptor tyrosine kinase pathways. EGFR expression is upregulated by direct binding of HOXB7 to the EGFR promoter, while HOXB7 functions as a cofactor with ERα to cause overexpression of multiple ER-target genes, including HER2, in tamoxifen resistant breast cancer cells. Probing the pathway further, we found that miR-196a and MYC are upstream regulators of HOXB7 expression. Mechanistically, HOXB7 and ERα jointly upregulate HER2 which phosphorylates MYC. Thus stabilized, MYC in turn suppresses miR-196a. Loss of miR-196a results lifts the quelling influence of miR-196a on HOXB7 expression. Besides shedding light on the intricate interplay of events occurring in tamoxifen resistant breast cancer, the work identifies a number of new therapeutic targets capable of restoring sensitivity of breast cancer cells to tamoxifen.
Insights
HOXB7 overexpression drives tamoxifen resistance in breast cancer by activating receptor tyrosine kinase pathways. Targeting HOXB7 and its regulators may restore tamoxifen sensitivity.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tamoxifen resistance is a major challenge in breast cancer treatment.
- The transcription factor HOXB7 is implicated in tamoxifen-resistant breast cancer.
Purpose of the Study:
- To elucidate the molecular mechanisms by which HOXB7 promotes tamoxifen resistance.
- To identify potential therapeutic targets for overcoming tamoxifen resistance.
Main Methods:
- Investigated HOXB7's role in regulating receptor tyrosine kinase (RTK) pathways.
- Analyzed the interplay between HOXB7, ERα, HER2, MYC, and miR-196a.
- Examined the direct binding of HOXB7 to the EGFR promoter.
Main Results:
- HOXB7 overexpression upregulates EGFR via direct promoter binding.
- HOXB7, as a cofactor with ERα, overexpresses HER2 and other ER-target genes.
- A feedback loop involving HER2, MYC, and miR-196a regulates HOXB7 expression.
Conclusions:
- HOXB7 drives tamoxifen resistance through RTK pathway activation and a novel regulatory loop.
- This study identifies HOXB7, EGFR, HER2, MYC, and miR-196a as potential therapeutic targets.
More Related Videos
08:48An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation
Published on: June 30, 2015
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Related Concept Videos
Hedgehog Signaling Pathway
Endocrine Signaling
Endocrine Signaling
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
mTOR Signaling and Cancer Progression
The mTOR pathway or the...